MUC1 and lymphoma: Our basic understanding of the functional and mechanistic involvement of MUC1-Cter in tumorigenesis resulted in development of peptide inhibitors such as GO-203-2C, which is under phase-I clinical trial (NCT01279603) against patients with advanced solid tumors and lymphoma.